LBRX · LB Pharmaceuticals Inc
United States · RS rating 85 · As of 2026-11-03
| Price | 40.33 USD |
|---|---|
| 1-day change | +3.3% |
| RS rating (overall / 1M / 3M / 12M) | 85 / 91 / 45 / 96 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 43 / 46 / 41 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +26.2% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +18.5% |
| Market cap (USD) | $882.5M |